Related Experiment Video
Updated: Sep 14, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Overexpressed MicroRNA-455-3p enhances cognitive function in late-onset Alzheimer's disease
Md Ariful Islam1, Sudhir Kshirsagar1, Rainier Vladlen Alvir1
1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Abstract:
MicroRNAs (miRNAs) are emerging as key regulators of neurodegenerative diseases, including Alzheimer's disease (AD). miR-455-3p has been implicated in neuronal function, yet its role in cognition, motor function, and behavioral responses, in relation to AD remains unexplored. This study investigates the effects of miR-455-3p overexpression and knockout in late-onset humanized Amyloid beta (hAbKI) mouse model. We crossed miR-455-3p transgenic (TG) and knockout (KO) mice with hAbKI mice, generated double mutant mice (miR-455-3p Tg X hAbKI and miR-455-3p KO X hAbKI) and assessed cognitive behavior. To evaluate behavioral phenotype, we used cognitive and motor tests in six experimental groups-wild-type (WT), miR-455-3p KO, miR-455-3p TG, hAbKI, miR-455-3p TG X hAbKI, and miR-455-3p KO X hAbKI-to the Morris Water Maze (MWM), Y-maze, open field, and rotarod tests. miR-455-3p overexpression in TG mice significantly enhanced locomotor activity (open field test), working memory (Y-maze), hippocampal spatial learning & memory (MWM), and motor coordination (rotarod test). In contrast, miR-455-3p KO and KO X hAbKI mice exhibited impaired cognitive functionand reduced motor performance. In addition, miR-455-3p KO and KO X hAbKI mice showed increased anxiety-like behavior in the light-dark (LD) test. Notably, the hAbKI X miR-455-3p KO group displayed the most severe deficits, suggesting that the loss of miR-455-3p exacerbates AD-related impairments. Statistical analyses confirmed significant group differences (p < 0.05), with post-hoc tests demonstrating superior performance in the TG group compared to KO and hAbKI X miR-455-3p KO mice. These findings suggest that miR-455-3p plays a significant role in regulating cognitive and motor functions, with its overexpression conferring neuroprotective benefits. Targeting miR-455-3p may provide novel strategies for improving cognitive and motor outcomes in AD and related conditions.
Insights
MicroRNA-455-3p (miR-455-3p) enhances cognitive and motor functions. Its overexpression offers neuroprotection, while its absence worsens Alzheimer's disease (AD) symptoms in mice.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- MicroRNAs (miRNAs) are critical regulators in neurodegenerative diseases like Alzheimer's disease (AD).
- The specific role of miR-455-3p in cognitive and motor functions related to AD was previously unexplored.
Purpose of the Study:
- To investigate the impact of miR-455-3p overexpression and knockout on cognitive and motor behaviors in a humanized amyloid beta (hAbKI) mouse model of AD.
Main Methods:
- Generated double mutant mice by crossing miR-455-3p transgenic (TG) and knockout (KO) mice with hAbKI mice.
- Assessed cognitive and motor functions using Morris Water Maze, Y-maze, open field, and rotarod tests across six experimental groups.
Main Results:
- miR-455-3p overexpression significantly improved locomotor activity, working memory, spatial learning, and motor coordination.
- miR-455-3p knockout impaired cognitive and motor performance and increased anxiety-like behavior.
- The hAbKI x miR-455-3p KO group showed the most severe deficits, indicating miR-455-3p loss exacerbates AD-related impairments.
Conclusions:
- miR-455-3p plays a crucial role in regulating cognitive and motor functions.
- Overexpression of miR-455-3p demonstrates neuroprotective benefits.
- Targeting miR-455-3p presents a potential therapeutic strategy for improving outcomes in AD and related disorders.
More Related Videos
09:06Stereotactic Injection of MicroRNA-expressing Lentiviruses to the Mouse Hippocampus CA1 Region and Assessment of the Behavioral Outcome
Published on: June 10, 2013
07:55Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
MicroRNAs
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists